|
    AXNX U.S.: Nasdaq

    Axonics Inc.

    AXNXUS
    After Hours
    Last Updated: Jan 20, 2022 4:29 p.m. EST Delayed quote

    $ 49.81

    0.00 0.00%
    After Hours Volume: 9.63K
    Close Chg Chg %
    $49.81 0.42 0.85%
    Advanced Charting
    Volume: 383.36K 65 Day Avg: 540.77K
    71% vs Avg
    49.56 Day Range 52.42
    46.96 52 Week Range 79.81

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    AXNX Overview

    Performance

    5 Day
    • -9.57%
    1 Month
    • -12.32%
    3 Month
    • -25.83%
    YTD
    • -11.05%
    1 Year
    • -8.29%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 8 Full Ratings

    Recent News

    Read full story

    W.R. Grace, Build-A-Bear See Activist Action

    Axonics Modulation Technologies started at buy with $38 stock price target at SunTrust RH

    Read full story

    Tribune, e.l.f beauty, Eastman Kodak, and other 13D Filings

    Axonics Modulation Technologies started at buy with $43 stock price target at Needham

    Axonics stock price target raised to $33 vs. $26 at SunTrust Robinson Humphrey

    Axonics Modulation Technologies started at overweight with $21 stock price target at Morgan Stanley

    Read full story

    Blue Harbor Springs on Jack in the Box Shares

    Shares of Orchard Therapeutics and Axonics Modulation falter in trading debut

    Axonics prices IPO at $15 a share

    Axonics to offer 6.7 million shares in IPO, priced at $14 to $16 each

    Axonics sets IPO terms, to offer 6.7 mln shares priced at $14 to $16 each

    Leerink Partners Sticks to Its Buy Rating for Axonics Modulation Technologies (AXNX)

    on TipRanks.com

    Morgan Stanley Remains a Buy on Axonics Modulation Technologies (AXNX)

    on TipRanks.com

    Axonics (AXNX) Soars 7.4%: Is Further Upside Left in the Stock?

    on Zacks.com

    Needham Sticks to Its Buy Rating for Axonics Modulation Technologies (AXNX)

    on TipRanks.com

    Axonics Modulation Technologies Inc (AXNX) Q3 2021 Earnings Call Transcript

    on Motley Fool

    Leerink Partners Maintains a Buy Rating on Axonics Modulation Technologies (AXNX)

    on TipRanks.com

    Needham Reaffirms Their Buy Rating on Axonics Modulation Technologies (AXNX)

    on TipRanks.com

    Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Misses Revenue Estimates

    on Zacks.com

    Analysts Conflicted on These Healthcare Names: Axonics Modulation Technologies (AXNX) and BioNTech SE (BNTX)

    on TipRanks.com

    Axonics: Buy at the High?

    on Motley Fool

    Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Axonics Modulation Technologies (AXNX) and NeoGenomics (NEO)

    on TipRanks.com

    Barclays Reaffirms Their Buy Rating on Axonics Modulation Technologies (AXNX)

    on TipRanks.com

    Axonics Modulation Technologies (AXNX) Reports Q2 Loss, Tops Revenue Estimates

    on Zacks.com

    Axonics Modulation Technologies (AXNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    on Zacks.com

    Wells Fargo Believes Axonics Modulation Technologies (AXNX) Still Has Room to Grow

    on SmarterAnalyst

    Wall Street Analysts Are Bullish on Top Healthcare Picks

    on SmarterAnalyst

    Morgan Stanley Maintains a Buy Rating on Axonics Modulation Technologies (AXNX)

    on SmarterAnalyst

    Needham Issues a Buy Rating on Axonics Modulation Technologies (AXNX)

    on SmarterAnalyst

    Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates

    on Zacks.com

    Axonics Modulation Technologies (AXNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    on Zacks.com

    Axonics Inc.

    Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.